Chirag PatelPresident and Co-Chief Executive Officer
Chirag Patel has served as Co-Chief Executive Officer, President and director of the Company since August 2019. Mr. Patel served as a Co-Chairman of the Board from May 2018 to August 2019, and previously was Co-Founder of Amneal and served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2005 to October 2017. With his brother, Chintu Patel, Mr. Patel has also invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv Biosciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Earlier in his career, Mr. Patel co-founded technology companies NextGen Technologies and Veriprise Wireless. Mr. Patel also serves as a Managing Trustee for the Liberty Science Center of New Jersey, a Director for the New Jersey City University Foundation and a Trustee for the Foundation for Morristown Medical Center. He is also a recipient of the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award®. Mr. Patel supports various philanthropic causes and, together with his wife, Priti Patel, established the Niswarth International Foundation in 2013. The Foundation aims to bring fresh water, sanitation, nutrition and education to underprivileged children. Mr. Patel received his bachelor’s degrees in Commerce from H.A. College of Commerce, India, and in Business Administration from New Jersey City University. He also holds an honorary Doctorate of Humane Letters from New Jersey City University in recognition of his efforts to serve others.
Chintu PatelCo-Chief Executive Officer
Chintu Patel has served as Co-Chief Executive Officer and director of the Company since August 2019. Mr. Patel served as a Co-Chairman of the Board from May 2018 to August 2019, and previously served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2002 until the combination with Impax Laboratories in 2018. With his brother, Chirag Patel, Mr. Patel also co-founded and invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv BioSciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Before founding Amneal, Mr. Patel was a pharmacist and senior-level manager with Eckerd Pharmacy from 1994 to 2002, where he won numerous awards. Mr. Patel has been a featured speaker at the Hauppauge Industrial Association in New York and serves on the boards of the Long Island Association, Long Island University, and the Make-a-Wish Foundation®, and is a recipient of the 2011 Ernst & Young National Entrepreneur of the Year Life Sciences Award®. Mr. Patel and his wife, Falguni Patel, run the Irada International Foundation, which focuses on health, education, and community outreach projects in India and the United States. Mr. Patel holds a bachelor’s degree in Pharmacy from Rutgers College of Pharmacy.
Andrew S. BoyerExecutive Vice President, Chief Commercial Officer – Generics
Andy serves as Executive Vice President, Chief Commercial Officer – Generics, and is focused on accelerating the sales, marketing and distribution of our evolving generics portfolio, including focusing on our growing injectables business. Andy most recently served as President and CEO of North America Generics, Teva Pharmaceuticals, Inc. Prior to joining Teva, Andy was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan plc (formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.) since September 2006. He joined then Watson in 1998 as Associate Director of Marketing in Generics. Before joining Watson, Andy served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Andy received his Bachelor’s degree in Business Administration and Management from State University of New York at Albany.
Robert L. Iser, M.S.Senior Vice President, Global Quality Management
Bob is responsible for global quality management at Amneal and has more than 20 years of U.S. FDA and biopharmaceutical industry experience in product development, manufacturing, quality systems, policy and procedure development and validation of analytical methods. Prior to joining Amneal, Bob served as Vice President, Regulatory Consulting Services for Parexel International, where he led the Strategic Compliance Team advising clients on developing global regulatory strategies. He is also a former 14-year veteran of the U.S. FDA/Center for Drug Evaluation and Research (CDER). During his tenure with FDA, he served various leadership roles of increasing responsibility across several offices at the Center for Drug Evaluation and Research (CDER), including the Office of Pharmaceutical Quality, Office of Pharmaceutical Science, and Office of Generic Drugs (OGD). Prior to joining FDA, Bob served Quality Control leadership roles for Eurand, Inc. – at the time a privately held pharmaceutical company. He holds an M.S. in Chemistry from Wright State University and a B.S. in Chemistry from Muskingum College.
Sanjay Kumar Jain, Ph.D.President • India
Sanjay has oversight for all aspects of Amneal India operations, including managing the overall productivity and quality deliverables. He has extensive experience managing Operations, Validation and Quality, as well as Regulatory audits originating from the USFDA, MHRA, EU, TGA, Anvisa, MCC and Health Canada. Prior to joining Amneal, Sanjay held Quality and Operations positions at Ranbaxy Laboratories, Zydus Cadila, Torrent Pharmaceuticals, Cadila Pharmaceuticals, Intas Pharmaceuticals, Bharat Parenterals and Mesco Pharmaceuticals. He has developed quality systems, implemented various process improvement projects, developed and audited API vendor sites across the globe and successfully faced regulatory audits of various regulatory agencies multiple times. Sanjay is a member of the International Society for Pharmaceutical Engineering (ISPE) and Parenteral Drug Association (PDA and an accomplished speaker at various international conferences. He holds a degree in Pharmacy, a post graduate degree in Quality Management (Masters in Science, Quality Management), and Ph.D. in Operation Management.
Tasos KonidarisExecutive Vice President, Chief Financial Officer
Tasos is responsible for leading Amneal’s global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Information Technology. He brings more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics/data industries. Tasos most recently served as Alcresta Therapeutics, Inc.’s Chief Financial Officer from 2016 to 2020, where he led the company’s finance, corporate development, information technology and human resources functions, and was instrumental in supporting the commercialization of a novel therapy to help critically ill patients and expand the company’s R&D pipeline. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria, Inc., from 2011 to 2015. In that role, he led finance and corporate development functions in delivering robust global organic growth as well as growth through licensing and acquisitions. Before joining Ikaria, Tasos served as Senior Vice President and Chief Financial Officer of Dun & Bradstreet Corporation for seven years, and previously held financial and general management roles of increasing responsibility at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation and Bristol-Myers Squibb. He currently serves as a Director on the boards of Kadmon Holdings and Zep Inc. He holds a B.S. in Mathematics and Finance from Gwynedd Mercy University and an M.B.A. from Drexel University.
Srinivas Kone, Ph.D.Senior Vice President, Global Generic R&D
Dr. Kone has leadership responsibility for Amneal’s Generic Research & Development activities, including overseeing the company’s global Complex Pharmaceutical Dosage Development, Regulatory Affairs and Portfolio and Project Management activities. He brings substantial R&D experience to Amneal and has served roles of increasing responsibility since joining the company in 2005. During his tenure, Dr. Kone has contributed significantly to the expansion of Amneal’s technical capabilities across new dosage forms, including leading the development of advanced programs in complex generic liquids, nasal sprays, topicals, transdermals, ophthalmics and inhalation. He has also played a key role in implementing innovative regulatory strategies that resulted in the delivery of several first-to-file and first-to-market opportunities and is deeply experienced in product lifecycle management. Prior to joining Amneal, Dr. Kone held R&D leadership roles for Zydus and Sun Pharmaceuticals. Dr. Kone received his Ph.D in Pharmacy from Andhra University, holds several patents and his research has been published in several journals of international acclaim.
Stephen J. ManzanoSenior Vice President, General Counsel & Corporate Secretary
Steve is responsible for leading Amneal’s global legal, Intellectual Property (IP) and corporate compliance functions, as well as aligning the company’s corporate legal strategies to drive Amneal’s continued growth. He brings more than 25 years of experience in private corporate and financial transactional practice as well as leading in-house corporate legal teams in the pharmaceutical sector. Most recently, Steve concurrently served for 11 years as Group Vice President, General Counsel, Secretary & Head of Corporate Compliance for both Sun Pharmaceuticals and majority-owned subsidiary, Taro Pharmaceuticals Industries. Steve holds a Bachelor of Science degree in Public Administration & Political Science from James Madison University and a Juris Doctor degree from Tulane Law School.
Nikita ShahExecutive Vice President, Chief Human Resources Officer and Strategic Planning Officer
Nikita serves as Executive Vice President, Chief Human Resources Officer and Strategic Planning Officer. In this role, she is responsible for overseeing Amneal’s Human Resources, Internal Communications and Corporate Social Responsibility functions. She also partners with the Co-CEOs to lead the creation and execution of the company’s long-term Corporate Strategy. Nikita joined Amneal in January 2014 as Senior Vice President, Human Resources & Corporate Affairs, and has served roles of increasing responsibility as a member of the company’s executive leadership team. Prior to joining Amneal, Nikita led the internal audit and human resources functions for Warner Chilcott, then a global specialty pharmaceutical company. She also supported corporate M&A, process improvements and systems efficiencies across the organization. Prior to Warner Chilcott, Nikita held leadership roles at AT&T and Deloitte. She holds a master’s degree in accounting and auditing from Gujarat University, India and is a certified public accountant.
Joseph TodiscoExecutive Vice President, Chief Commercial Officer – Specialty
Joe has leadership responsibility for the commercial and business development strategies driving the growth of Amneal’s Specialty business. In this role, he leads Specialty Sales and Marketing, Commercial Operations, Field Sales and Specialty Corporate Development. Joe joined Amneal in 2012 as Head of Corporate Development, serving an integral role in the execution and integration of the Amneal + Impax business combination, as well as multiple other business development, licensing and M&A transactions. In addition to his role in Corporate Development, Joe previously held management responsibility for Gemini Laboratories, building the company from inception to a highly profitable specialty pharmaceutical platform. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy’s North American Commercial Strategy and Business Development, and held various leadership roles with Par Pharmaceuticals. Prior to working in the pharmaceutical industry, Joe was an investment banker for Oppenheimer & Co. and also worked in financial services for Marsh & McLennan Companies. Joe holds a bachelor’s degree in Economics from Georgetown University in Washington D.C. and an M.B.A. from Fordham Graduate School of Business in New York.